In a world where cancer treatment is increasingly defined by expensive immunotherapies and highly specialized genetic interventions, an unexpected contender has emerged from one of medicine’s oldest shelves: aspirin.
A landmark international clinical trial is now drawing global attention to the humble painkiller, revealing that a simple daily dose of aspirin may significantly reduce the recurrence of colorectal cancer in a specific group of patients. For Kenya — where access to advanced cancer care remains limited for many — the implications could be profound.
Breakthrough Findings from Sweden
The findings come from the ALASCCA trial, led by researchers at Karolinska Institutet, one of Europe’s leading medical research institutions. The study followed more than 3,500 colorectal cancer patients after surgery, focusing on tumors with mutations in the PI3K signaling pathway — a genetic alteration found in roughly 37 percent of colorectal cancer cases.
Participants were randomly assigned to receive either a 160 mg daily dose of aspirin or a placebo for three years.
The results were striking.
Among patients with the targeted genetic mutations, only 7.7 percent of those taking aspirin experienced a recurrence of cancer, compared to 14.1 percent in the placebo group — effectively cutting the recurrence risk by nearly half.
Professor Anna Martling described the findings as a major step in precision medicine.
“Aspirin is being tested here in a completely new context as a precision medicine treatment,” she said, noting that the study demonstrates how genetic information can guide affordable, personalized care.
Why This Matters for Kenya
Colorectal cancer is becoming an increasingly urgent public health concern in Kenya. By 2025, it had become the country’s fifth most common cancer, contributing to a growing national cancer burden. With over 102,000 cases recorded in Kenya’s five-year cancer prevalence data, colorectal cancer represents a rising share of diagnoses.
For many Kenyan patients, surgery remains the main line of treatment. Yet even after successful tumor removal, the risk of recurrence remains a serious challenge due to microscopic cancer cells that may remain undetected.
This is where aspirin’s new role could become transformative. Unlike costly modern cancer drugs, aspirin is widely available and inexpensive in Kenya. A month’s supply of low-dose aspirin often costs less than a basic meal, making it one of the most accessible medicines in the country.
For a healthcare system where affordability can determine survival, repurposing such a low-cost drug offers hope for broader access to effective post-surgical care.
Potential Impact on Cancer Care
Experts say the implications for Kenya’s oncology landscape could be significant. First, if molecular testing for PI3K mutations becomes more accessible through public-private partnerships, doctors could identify patients most likely to benefit from aspirin therapy.
This would allow for targeted, cost-effective survivorship plans — reducing the need for expensive secondary treatments and intensive recurrence monitoring.
Second, improved survival outcomes could be within reach.
Emerging local studies have already suggested that aspirin users in Kenya may live significantly longer than non-users. Integrating these findings into formal treatment guidelines could create a low-cost safety net for thousands of colorectal cancer survivors.
Despite the promise, aspirin is not suitable for everyone.
Medical experts warn that long-term use can increase the risk of gastrointestinal bleeding and other complications, particularly in patients with ulcers or clotting disorders.
This means aspirin therapy should only be prescribed under professional medical supervision, following proper genetic and clinical assessment. In short, the breakthrough is not about self-medication — it is about smarter, more personalized treatment.
A New Era of Affordable Precision Medicine
The ALASCCA trial signals a shift toward a future where cancer treatment is not only personalized, but also practical. In an era where precision medicine is often associated with high costs, aspirin offers a powerful reminder that innovation does not always come in the form of new inventions.
Sometimes, it comes from rediscovering the value of what has been with us all along. For Kenya and other developing nations, this could mark the beginning of a more affordable and accessible approach to cancer care — one where a common household medicine helps rewrite survival stories.
About The Author
